The Association between Metabolic Syndrome and Multiple Myeloma
Open Access
- 14 May 2020
- journal article
- review article
- Published by S. Karger AG in Acta Haematologica
- Vol. 144 (1), 24-33
- https://doi.org/10.1159/000505992
Abstract
Multiple myeloma (MM) is a haematological malignancy arising from monoclonal proliferation of plasma cells in the bone marrow, resulting in the presence of paraproteins or M-protein in serum. The involvement of paraproteins produced by malignant plasma cells in the development of hyperlipidaemia and low-HDL cholesterol has been described, as has an association with MM and obesity, hypertension, and type 2 diabetes mellitus, and insulin resistance, that is, features of the metabolic syndrome (MS). There is an association between MS components, inflammatory cytokines, and the development of MM, and some drugs used in the treatment of MS such as statins and metformin may improve outcomes in MM.Keywords
This publication has 92 references indexed in Scilit:
- Metabolic Syndrome and Risk of CancerDiabetes Care, 2012
- Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studiesBlood, 2012
- Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone diseaseBlood, 2011
- Body-Mass Index and Mortality among 1.46 Million White AdultsThe New England Journal of Medicine, 2010
- Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or MyelomaThe Oncologist, 2010
- Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer CellsPublished by Elsevier BV ,2010
- The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorBlood, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Obesity and insulin resistanceJCI Insight, 2000